Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 28 of 28 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ERBB3 positive	Her2-receptor negative breast cancer	predicted - sensitive	Patritumab deruxtecan	Phase II	Actionable	In a Phase II trial, Patritumab deruxtecan (U3-1402) treatment resulted in an objective response rate (ORR) of 35%, clinical benefit rate (CBR) of 48%, median duration of response of 10 mo, and 6-mo progression-free survival (PFS) rate of 60% in ERBB3 (HER3)-positive, ERBB2 (HER2)-negative metastatic breast cancer patients, with an ORR of 46 vs 33%, CBR of 54 vs 50%, and PFS rate of 70 vs 50% in those with 25-75% vs >/=75% ERBB3 (HER3) expression (J Clin Oncol 41, 2023 (suppl 16; abstr 1004); NCT04699630).	detail...
ERBB3 positive	Her2-receptor negative breast cancer	predicted - sensitive	Patritumab deruxtecan	Phase Ib/II	Actionable	In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic hormone receptor-positive, ERBB2 (HER2)-negative breast cancer patients expressing ERBB3 (HER3) (n=113), with an objective response rate of 30.1%, disease control rate of 80.5%, with partial response in 30.1% and stable disease in 50.4% of patients, median progression-free survival of 7.4 mo, and median overall survival of 14.6 mo (PMID: 37801674; NCT02980341).	37801674
ERBB3 positive	Advanced Solid Tumor	sensitive	Lumretuzumab	Phase I	Actionable	In a Phase I trial, Lumretuzumab treatment resulted in stable disease in 21.3% (10/47) of patients with Erbb3 (Her3)-expressing advanced solid tumors (PMID: 26463709).	26463709
ERBB3 positive	triple-receptor negative breast cancer	sensitive	Lumretuzumab	Phase I	Actionable	In a Phase I trial, Lumretuzumab treatment resulted in tumor shrinkage in a patient with Erbb3 (Her3)-expressing triple-receptor negative breast cancer (PMID: 26463709).	26463709
ERBB3 positive	head and neck squamous cell carcinoma	predicted - sensitive	CDX-3379	Phase I	Actionable	In a Phase I trial, CDX-3379 (KTN3379) treatment decreased tumor Erbb3 phosphorylation levels in 83% (10/12) of patients with head and neck squamous cell carcinoma, with 50% or more reduction in 58% (7/12) of patients, and 42% (5/12) patients achieved shrinkage of tumor burden (PMID: 31308059; NCT02473731).	31308059
ERBB3 positive	Her2-receptor negative breast cancer	predicted - sensitive	Patritumab deruxtecan	Clinical Study	Actionable	In a clinical study, Patritumab deruxtecan (U3-1402) treatment demonstrated efficacy in patients with ERBB3 (HER3)-positive, ERBB2 (HER2)-negative breast cancer, resulting in increased immune infiltration as measured by a median increase of 3.5 in the CelTIL score, and an overall response rate of 45.2% (28/62, 14 complete and 14 partial responses) (PMID: 37211044; NCT04610528).	37211044
ERBB3 positive	esophagus adenocarcinoma	sensitive	AMT-562	Preclinical - Pdx	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive esophageal adenocarcinoma (PMID: 37302522).	37302522
ERBB3 positive	esophagus squamous cell carcinoma	sensitive	AMT-562	Preclinical - Pdx	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive esophageal squamous cell carcinoma (PMID: 37302522).	37302522
ERBB3 positive	gastroesophageal junction adenocarcinoma	sensitive	AMT-562	Preclinical - Pdx	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive gastroesophageal junction adenocarcinoma (PMID: 37302522).	37302522
ERBB3 positive	lung non-small cell carcinoma	sensitive	DB-1310	Preclinical - Pdx	Actionable	In a preclinical study, DB-1310 inhibited tumor growth in ERBB3 (HER3)-positive non-small cell lung cancer cell line xenograft and patient-derived xenograft (PDX) models (PMID: 38632563).	38632563
ERBB3 positive	prostate cancer	sensitive	DB-1310	Preclinical - Pdx	Actionable	In a preclinical study, DB-1310 inhibited tumor growth in ERBB3 (HER3)-positive prostate cancer patient-derived xenograft (PDX) models (PMID: 38632563).	38632563
ERBB3 positive	colorectal cancer	sensitive	Patritumab deruxtecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Patritumab Deruxtecan (U3-1402) decreased viability of Erbb3 (Her3)-positive colorectal cancer cell lines in culture and induced significant tumor growth inhibition in cell line xenograft models with intermediate to high Erbb3 (Her3) expression (PMID: 31395690).	31395690
ERBB3 positive	colorectal cancer	predicted - sensitive	Patritumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Patritumab treatment resulted in reduced Erbb3 (Her3) phosphorylation in Erbb3 (Her3)-positive colorectal cancer cell lines in culture and modest antitumor activity in cell line xenograft models (PMID: 31395690).	31395690
ERBB3 positive	colon cancer	sensitive	ISU104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in a colon cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100).	33782100
ERBB3 positive	head and neck squamous cell carcinoma	sensitive	ISU104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in head and neck squamous carcinoma cell lines in culture, and resulted in tumor regression in cell line xenograft models (PMID: 33782100).	33782100
ERBB3 positive	pancreatic cancer	sensitive	ISU104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation, downstream signaling, and proliferation of pancreatic cancer cells in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100).	33782100
ERBB3 positive	breast cancer	sensitive	ISU104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation, downstream signaling, and proliferation in breast cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 33782100).	33782100
ERBB3 positive	lung non-small cell carcinoma	sensitive	ISU104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in a non-small cell lung cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100).	33782100
ERBB3 positive	skin cancer	sensitive	ISU104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ISU104 treatment inhibited Erbb3 phosphorylation and downstream signaling in a skin cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33782100).	33782100
ERBB3 positive	breast cancer	predicted - sensitive	DB-1310	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DB-1310 inhibited tumor growth in an ERBB3 (HER3)-positive breast cancer cell line xenograft model (PMID: 38632563).	38632563
ERBB3 positive	lung non-small cell carcinoma	sensitive	AMT-562	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of ERBB3 (HER3)-positive non-small cell lung cancer (PMID: 37302522).	37302522
ERBB3 positive	colon cancer	sensitive	AMT-562	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of ERBB3 (HER3)-positive colon cancer with a complete response in 4 of 5 mice and inhibited growth in patient-derived organoids in culture (PMID: 37302522).	37302522
ERBB3 positive	breast cancer	predicted - sensitive	AMT-562	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of low ERBB3 (HER3)-expressing breast cancer (PMID: 37302522).	37302522
ERBB3 positive	stomach cancer	sensitive	AMT-562	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMT-562 inhibited tumor growth in a cell line xenograft model of ERBB3 (HER3)-positive gastric cancer (PMID: 37302522).	37302522
ERBB3 positive	colon cancer	sensitive	DB-1310	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DB-1310 inhibited tumor growth in an ERBB3 (HER3)-positive colon cancer cell line xenograft model (PMID: 38632563).	38632563
ERBB3 positive	melanoma	sensitive	Canertinib	Preclinical	Actionable	In a preclinical study, ERBB3 (HER3)-positive melanoma cells were sensitive to Canertinib, resulting in decreased metastasis in mouse models (PMID: 25000258).	25000258
ERBB3 positive	melanoma	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation and ERBB3 (HER3)-AKT signaling in a human melanoma cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266).	26880266
ERBB3 positive	breast cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation of a human breast cancer cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266).	26880266

Showing 1 to 28 of 28 entries

Filter rows:

Profile Name	ERBB3 positive
Gene Variant Detail	ERBB3 positive (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting